Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macs@EcN IL-15
- Development stage
- Preclinical
- Lead developer
- Nanjing University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Cell Therapies
- Administration
- Intravesical
01
Overview
Macs@EcN IL-15 is a preclinical-stage, macrophage-encapsulated engineered bacterial therapy developed by Nanjing University for the treatment of bladder cancer. The therapeutic agent consists of a recombinant *Escherichia coli* Nissle 1917 (EcN) strain engineered to express and secrete an interleukin-15 (IL-15) and IL-15 receptor alpha (IL-15Rα) fusion protein (EcN IL-15). This engineered strain is encapsulated within bone marrow-derived macrophages (BMDMs), which leverage their natural tumor-specific tropism and adhesion capabilities to target bladder tumors. Upon intravesical administration, the macrophages deliver the bacteria directly to the tumor microenvironment, where the sustained release of the IL-15/IL-15Rα complex activates and expands T cells and natural killer (NK) cells, promoting localized, durable antitumor immune responses.
- Other names
- EcN IL-15EcNIL-15EcNIL15EcNIL 15macrophage-encapsulated engineered EcN expressing IL-15 & IL-15Ra fusion proteinmacrophage-encapsulated engineered EcN expressing IL-15 & IL-15Rα fusion protein
02
Targets
Beyond the preview
Go deeper on Macs@EcN IL-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Macs@EcN IL-15.